Compare BRCB & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRCB | SGHT |
|---|---|---|
| Founded | 2008 | 2011 |
| Country | United States | United States |
| Employees | 2800 | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 206.8M | 235.0M |
| IPO Year | N/A | 2021 |
| Metric | BRCB | SGHT |
|---|---|---|
| Price | $7.20 | $5.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $24.83 | $9.08 |
| AVG Volume (30 Days) | ★ 388.6K | 324.5K |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $77,363,000.00 |
| Revenue This Year | $30.74 | $11.67 |
| Revenue Next Year | $24.06 | $10.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.61 | $3.11 |
| 52 Week High | $30.40 | $9.24 |
| Indicator | BRCB | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 19.44 | 63.62 |
| Support Level | N/A | $4.86 |
| Resistance Level | $15.72 | $5.25 |
| Average True Range (ATR) | 0.81 | 0.37 |
| MACD | -0.44 | 0.08 |
| Stochastic Oscillator | 1.76 | 74.05 |
Black Rock Coffee Bar Inc is an operator of guest-centric, drive-thru coffee bars offering premium caffeinated beverages and an elevated in-store experience crafted by its engaging baristas. The company offers wide variety of coffee from classic espresso-based drinks such as Lattes, Americanos, and Cappuccinos, as well as signature creations like the Caramel Blondie, Mexican Mocha, and Blackout. It offers a variety of savory and sweet items, including breakfast burritos, sausage cheddar sandwiches, banana bread, and glazed donut holes.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.